News | July 11, 2007

GE, Abbott Labs Call Off $8.13 Billion Diagnostics Deal

A WALL STREET JOURNAL ONLINE NEWS ROUNDUP
July 11, 2007 - General Electric Co. and Abbott Laboratories announced they have terminated GE's $8.13 billion deal to buy Abbott's primary in-vitro and point-of-care diagnostics businesses.

In separate statements, the companies said they were unable to agree on "final terms and conditions" of the proposed deal. As a result, according to GE's statement, the companies "agreed it was in the best interests of both companies to mutually terminate their agreement and discussions."

The acquisition would have marked GE's entry into what is known as "in vitro" diagnostics, or laboratory testing, while Abbott would have shed a unit growing more slowly than other parts of its business. In vitro" diagnostics generally test blood or urine for diseases from cancer to HIV. Germany's Siemens AG, a GE rival in medical equipment, entered the market last year by paying $5.3 billion for Bayer AG's diagnostic unit.

The Abbott unit had sales of roughly $2.5 billion last year. GE would also have acquired Abbott's smaller point-of-care diagnostic group, which makes testing tools used at the bedside in hospitals, among other diagnostic tools.

Source: The Wall Street Journal Online

For more information: www.gehealthcare.com and www.abbott.com

Related Content

CIRS, Dynamic Cardiac Phantom, CT, RSNA 2015

Image courtesy of CIRS Inc.

Technology | Quality Assurance (QA) | November 24, 2015
The Dynamic Cardiac Phantom is a precision instrument which mimics the translation and rotational motion of the heart...
Overlay Init